Pomalidomide

Drug Profile

Pomalidomide

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalyst

Latest Information Update: 19 Feb 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytokine modulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Phase I Waldenstrom's macroglobulinaemia
  • No development reported Myelofibrosis; Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer

Most Recent Events

  • 11 Jan 2017 Celgene Corporation initiates enrolment in a phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in United Kingdom (IV) (ISRCTN14749537)
  • 06 Dec 2016 Celgene completes a phase I trial for Multiple myeloma (Combination therapy, Second line therapy or greater) in USA and Australia (PO)
  • 03 Dec 2016 Interim adverse events, PD and efficacy data from the phase II MM-014 trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top